parkinson study group

Name

parkinson study group

Legal name

Parkinson Study Group

Website

https://parkinson-study-group.org

Company type

Private

Founded year

1986

Operating status

Operating

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Site Identification & Feasibility (HLAGACAB), Investigator & Site Training / GCP Support (HLAGACAF), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Clinical trial network
• Parkinson disease research
• Clinical research services
• Investigator credentialing
• Multi-site clinical trials

Headquarters

HQ city

East Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Foundation Support: Primary funding from Parkinson's Foundation and Michael J. Fox Foundation grants supporting clinical research, mentorship programs, and study conduct.
2. Donations: Accepts charitable donations from individuals to support ongoing clinical trials, development of new trials, and mentorship programs in PD.
3. Clinical Trial Services: Provides comprehensive clinical trial coordination services to pharmaceutical sponsors including protocol creation, FDA applications, site selection, and data management.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Parkinson Study Group (PSG) operates the largest non-profit cooperative clinical trial site network in North America for Parkinson's disease research, comprising over 155 credentialed sites and more than 375 credentialed investigators across the United States and Canada. PSG provides clinical trial coordination services to pharmaceutical sponsors — including protocol creation, FDA application support, site selection, and data management — and offers investigator credentialing, membership, mentorship programs, annual scientific meetings, and public access to datasets from completed PD trials.

Product overview

The Parkinson Study Group is a non-profit clinical trial site network (not a traditional product company) focused on Parkinson's Disease research. Its primary offering is the PSG Clinical Trial Network, which comprises over 155 credentialed sites and 375+ investigators conducting PD clinical trials. Supporting services include the PSG Credentialing Program for investigator/site qualification, PSG Membership Program with three membership categories, and the PSG Annual Meeting. PSG also offers research mentorship programs including the Mentored Clinical Research Award (MCRA), Visiting Mentorship Program (VMP), Coordinator Visiting Mentorship Program (CVMP), Junior Investigator Workshop, and Coordinator Workshop. Additional offerings include eight Working Groups for specialized research collaboration, Coordinator Support Line, Site Capabilities Survey, Job Postings platform, and PSG Study Data access for completed trial datasets.

Differentiator

Problem solved

Functional benefit

Products and services

• PSG Clinical Trial Network A non-profit cooperative clinical trial site network for Parkinson's disease research comprising over 155 sites with more than 375 credentialed investigators across North America, providing multi-site clinical trial coordination, protocol creation, FDA application support, site selection, and data management services to pharmaceutical sponsors.
• PSG Membership Program Membership program offering Investigator, Coordinator, and Community/Industry Partner membership categories, providing access to PSG working groups, resources, and networking opportunities for Parkinson's disease investigators and research staff.
• PSG Annual Meeting Annual scientific conference for PSG members featuring scientific sessions, abstract presentations, Junior Investigator Workshop, Coordinator Workshop, and networking opportunities for credentialed investigators and coordinators in Parkinson's disease research.
• PSG Study Data Public access datasets from completed PSG studies including SURE-PD3, STEADY-PD III, and DATATOP, containing clinical data, blood chemistry, neuroimaging, and whole genome sequencing data, made available for further Parkinson's disease research.
• Mentored Clinical Research Award (MCRA) Research funding award of up to $75,000 supporting early-career investigators in patient-oriented clinical research in Parkinson's disease, with an 18-month funding period, sponsored by the Parkinson's Foundation.
• PSG Credentialing Program A credentialing process for investigators and sites to participate in PSG clinical trials, with three classifications: Full Approval, Provisional Approval, and Study-specific Approval, qualifying movement disorders fellowship-trained clinician-trialists across North America.

Quantifiable outcome

• Completed 50+ Parkinson's studies with 8,000+ patients enrolled on deadline
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• Parkinson's FoundationcoreStrategic or Co-development PartnerMajor funder supporting the Mentored Clinical Research Award (MCRA) and other PSG programs. Partnership on patient engagement in research design and implementation for over ten years, including training resources for study coordinators.
• Michael J. Fox FoundationcoreStrategic or Co-development PartnerPrimary funder for multiple PSG studies including SURE-PD3, NIC-PD, and the DATATOP biospecimen repository. Collaborates on biomarker identification and validation programs using DATATOP resources.
• UCB PharmacoreStrategic or Co-development PartnerSponsor of the PSG Orchestra Study (NCT04658186), a Phase 2a study evaluating oral UCB0599 for early-stage Parkinson's disease.
• BIALcoreStrategic or Co-development PartnerSponsor of the ACTIVATE study (NCT05819359), a Phase II trial of BIA 28-6156 for GBA-PD patients with glucocerebrosidase mutations.
• BiogenminorStrategic or Co-development PartnerFunded WATCH-PD study and SPARK trial (BIIB054) for Parkinson's disease research.
• National Institute of Neurological Disorders and Stroke (NINDS)coreStrategic or Co-development PartnerFunded major PSG trials including SURE-PD3 and STEADY-PD III. Manages access to DATATOP biospecimen repository through PD-BRAC program.
• NeuroPoint AllianceminorStrategic or Co-development PartnerCollaborated on RAD-PD registry for advancement of Deep Brain Stimulation in Parkinson's disease, funded by Michael J. Fox Foundation.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Huntington Study Group: Long-standing non-profit, multi-site clinical trial network exclusively dedicated to Huntington's disease research. Closest analog to PSG: identical operating model (cooperative investigator network, single-disease focus, pharma + foundation sponsorship), differing only in the disease category.
• TREAT-NMD Alliance: Global neuromuscular disease clinical trial network coordinating multi-site studies across Europe and beyond. Comparable to PSG as a non-profit, disease-specialized site network with academic and pharma-sponsor engagement, though serving a different therapeutic area.
• NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials): NIH-funded cooperative clinical trial network for neurological diseases including Parkinson's. Overlaps with PSG in neurology trial site coordination, credentialing, and academic-pharma partnership execution, operating as a parallel infrastructure rather than strict competitor on PD-specific trials.
• Cystic Fibrosis Foundation Therapeutics Development Network: Disease-specific non-profit clinical trial site network for cystic fibrosis, structurally analogous to PSG with funding, site credentialing, and multi-site coordination functions concentrated within one therapeutic area.
• Alzheimer's Disease Cooperative Study (ADCS): Academic-led clinical trial coordinating center at UC San Diego running multi-site trials in Alzheimer's disease. Direct peer of PSG in neurodegenerative clinical trial site operations, study coordination, and pharma-sponsor service delivery model.

Broad incumbents

• IQVIA: World's largest CRO with global site network, DCT technology platform, and dedicated CNS therapeutic teams. Competes with PSG on large multi-region Parkinson's trials where global footprint, electronic clinical outcome assessment, and decentralized trial tooling are required.
• Parexel International: Large global CRO with neuroscience therapeutic expertise and extensive site relationships. Overlaps with PSG in serving pharma sponsors running Parkinson's trials, differentiated by global scale, commercial pricing, and end-to-end trial operations capabilities.
• Worldwide Clinical Trials: Mid-sized CRO with deep CNS/neurology specialization that runs Parkinson's disease trials for pharma sponsors. Competes with PSG for sponsor outsourcing budgets, especially for registrational and Phase II/III PD studies, but operates a commercial (not non-profit) model with broader therapeutic coverage.

Emerging players

• Critical Path Institute (C-Path): Non-profit consortium that develops regulatory-grade clinical trial tools and endpoint standards, including in Parkinson's disease. Adjacent to PSG in the PD research ecosystem — supports trial design and regulatory science that complement PSG's site execution capabilities.

Others

• Michael J. Fox Foundation (MJFF) Research CRO Operations: Major Parkinson's research funder that also runs its own sponsored clinical studies (e.g., PPMI) and supports PSG-funded trials. Functions as a sponsor/partner rather than direct competitor, but represents the largest single funding counterparty for PSG's grant- and contract-based activities.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/parkinson-study-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about parkinson study group